All In Biotech

Drug Trial Radar · NCT01767415

Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

Last checked: Nov 19, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Apr 2012

Primary completion

Apr 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Weill Medical College of Cornell UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate whether stereotactic indigo carmine injection can safely increase the extent of tumor resection.

Conditions

  • Brain Tumors With Ill-defined Margins

Interventions

  • Indigo carmineDrug

    During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Extent of ResectionTime frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Weill Cornell Medical College Department of Neurological Surgery

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.